What is Optimal Blood Pressure?

In the last 30 years, the clinical practice guidelines on both sides of the Atlantic have been lowering blood pressure thresholds. From the starting 160 mmHg systolic blood pressure to 130 mmHg or even 120 mmHg. 

Las nuevas guías Europeas de Hipertensión contrastan con las Americanas

In 2017, the American and the ACC/AHA guidelines were the first to lower said threshold, followed by the European ESC/ESH in 2018 and more recently by the National Institute for Health and Care Excellence (NICE) in August 2019.

With several points in common, they also differ in recommendations. The blood pressure target is still controversial, with 120 mmHg in patients for the ACC/AHA, 120-129 for the young and 130-139 mmHg for the elderly in the European guidelines, and the classic 140/90 for the conservative NICE guidelines.

With the kidneys as one of the main blood pressure targets, the new markers of lesion, inflammation and tubule fibrosis could be the ones to tell the adequate blood pressure threshold for each patient. 


Read also: Secondary Prevention: A Responsibility We Should Not Delegate.


The SPRINT study assessed 2377 hypertensive patients measuring alfa1 and beta2 microglobulin concentration, which was associated with major cardiovascular events, while uromodulin showed an inverse correlation.

Alfa 1 microglobulin twice as high as baseline was associated to the classic major events composite (death, infarction, stroke) as well as separate mortality, with 1.25 HR.

A two-fold higher uromodulin concentration was associat3ed to significant reduction of combined events, with HR 0.79, but this was not enough to reduce mortality considered separately. 


Read also: Benefit of Anticoagulation in the Elderly with Atrial Fibrillation.


The clinical value of these markers to adjust the “ideal” threshold in our patients should be further and discussed and studied.

Original Title: What is the optimal blood pressure?Differences between current guidelines and novel insights into kidney injury.

Reference: Thomas F. Lüscher. European Heart Journal (2019) 40, 3443–3446.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

Drugs for the Treatment of No-Reflow During PCI

The no-reflow phenomenon is one of the most frustrating complications of primary angioplasty (pPCI), reflecting persistent microvascular damage that, in the mid- to long-term,...

CRT 2026 | Clopidogrel vs Aspirin as Long-Term Monotherapy After Coronary Angioplasty

The use of aspirin as chronic antiplatelet therapy after percutaneous coronary intervention (PCI) has historically been the standard recommended by international guidelines. However, recent...

Low-Dose Rivaroxaban After Peripheral Angioplasty: Effectiveness and Safety in Real-World Clinical Practice

Following lower limb revascularization, optimal medical therapy includes antiplatelet agents, high-intensity statins, and control of cardiovascular risk factors. Recent studies such as COMPASS and...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | CHIP-BCIS3: Impella use as support in high-risk complex PCI

The use of percutaneous ventricular support during high-risk complex PCI has been proposed as a strategy to prevent hemodynamic deterioration in patients with severe...

ACC 2026 | ORBITA-CTO: PCI in chronic total occlusions and stable angina — the randomized trial we were missing?

Percutaneous coronary intervention (PCI) for chronic total occlusions (CTO) remains a topic of ongoing debate in stable angina, with persistent uncertainty regarding its role...

ACC 2026 | FAST III: vFFR vs FFR in physiology-guided revascularization of intermediate coronary lesions

Physiological assessment of intermediate coronary lesions remains a cornerstone in decision-making for coronary revascularization. Although FFR continues to be one of the guideline-recommended references,...